Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:03:06 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:AVXL - ANAVEX LIFE SCIENCES CORPORATION - https://www.anavex.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AVXL - Q5.04.11·4.501.74.10+0.297.61,681.36,5237,2073.86  4.26  3.8213.99  2.8619:58:52Feb 0315 min RT 2¢

Recent Trades - Last 10 of 7207
Time ETExPriceChangeVolume
19:58:52Q4.250.442
19:32:37Q4.230.4250
18:04:22Q4.120.3182
18:04:22Q4.12010.310182
17:33:21Q4.24760.437650
16:10:04Q4.100.291
16:10:04Q4.100.291
16:04:56Q4.100.291
16:04:37Q4.100.291
16:04:24Q4.100.291

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-03 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
2026-01-13 07:30U:AVXLNews ReleaseAnavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease
2026-01-08 07:30U:AVXLNews ReleaseAnavex Life Sciences Appoints Senior Vice President Global Head of Neurology
2026-01-06 07:30U:AVXLNews ReleaseAnavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program
2025-12-18 07:30U:AVXLNews ReleaseAnavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
2025-12-12 16:05U:AVXLNews ReleaseAnavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
2025-11-26 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
2025-11-25 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
2025-11-19 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
2025-11-18 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
2025-11-14 07:30U:AVXLNews ReleaseAnavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
2025-10-29 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group
2025-10-10 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care'
2025-10-02 07:35U:AVXLNews ReleaseAnavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX(TM)3-71 Program
2025-10-02 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX(TM)3-71 for the Treatment of Schizophrenia
2025-09-30 08:30U:AVXLNews ReleaseAnavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial
2025-09-09 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial
2025-09-02 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
2025-08-26 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
2025-08-20 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease